MEDI5752 in Japanese Patients With Advanced Solid Tumors.

Study identifier:D7980C00006

ClinicalTrials.gov identifier:NCT05685472

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Japanese Subjects with Advanced Solid Tumors

Medical condition

Advanced Solid Tumors

Phase

Phase 1

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

6

Study type

Interventional

Age

18 Years - 120 Years

Date

Study Start Date: 08 Dec 2022
Primary Completion Date: 08 Aug 2023
Estimated Study Completion Date: 11 Mar 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria